Enanta Pharmaceuticals up on fast-track tag from FDA for RSV drug

Enanta Pharmaceuticals

06/04/2023 16:28

** Enanta Pharmaceuticals Inc's  ENTA.O  shares up 2.6% at
$39.48
    ** Drug developer says U.S. FDA grants fast-track
designation for company's respiratory syncytial virus (RSV) drug
    ** Fast-track designation designed to accelerate development
and review of products, which are intended to treat serious
diseases 
    ** Drug candidate currently in early-stage study to assess
safety and tolerability, data from study expected to be reported
this quarter - ENTA
    ** Including session's gains, ENTA down ~15% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com))